James Vannucci

Array ( [id] => 18980166 [patent_doc_number] => 11905326 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-20 [patent_title] => Multispecific heavy chain antibodies binding to CD22 and CD3 [patent_app_type] => utility [patent_app_number] => 16/900586 [patent_app_country] => US [patent_app_date] => 2020-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 23 [patent_no_of_words] => 18574 [patent_no_of_claims] => 97 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16900586 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16525290 [patent_doc_number] => 20200399370 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-24 [patent_title] => Agents for Treatment of Claudin Expressing Cancer Diseases [patent_app_type] => utility [patent_app_number] => 16/898892 [patent_app_country] => US [patent_app_date] => 2020-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62201 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16898892 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16635305 [patent_doc_number] => 10913800 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-09 [patent_title] => Anti-transferrin receptor antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/896995 [patent_app_country] => US [patent_app_date] => 2020-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 27 [patent_no_of_words] => 43132 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16896995 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18315117 [patent_doc_number] => 11629186 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-18 [patent_title] => Anti-CCL8 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/895407 [patent_app_country] => US [patent_app_date] => 2020-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 21 [patent_no_of_words] => 8432 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16895407 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16557211 [patent_doc_number] => 20210002359 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => IMMUNOGLOBULIN VARIANTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/889510 [patent_app_country] => US [patent_app_date] => 2020-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51642 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16889510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20438676 [patent_doc_number] => 12509503 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-30 [patent_title] => Pan-neuraminidase inhibiting antibodies [patent_app_type] => utility [patent_app_number] => 17/615309 [patent_app_country] => US [patent_app_date] => 2020-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 45 [patent_no_of_words] => 19581 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 271 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17615309 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18013322 [patent_doc_number] => 11505604 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-22 [patent_title] => Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer [patent_app_type] => utility [patent_app_number] => 16/874826 [patent_app_country] => US [patent_app_date] => 2020-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 22 [patent_no_of_words] => 44378 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1065 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16874826 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20357370 [patent_doc_number] => 12473353 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-18 [patent_title] => Antigen-binding molecule, a pharmaceutical composition, and a method [patent_app_type] => utility [patent_app_number] => 17/610204 [patent_app_country] => US [patent_app_date] => 2020-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 38724 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17610204 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16397303 [patent_doc_number] => 20200338161 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => BTNL9 AND ERMAP AS NOVEL INHIBITORS OF THE IMMUNE SYSTEM FOR IMMUNOTHERAPIES [patent_app_type] => utility [patent_app_number] => 16/867500 [patent_app_country] => US [patent_app_date] => 2020-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4652 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16867500 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17307393 [patent_doc_number] => 11208486 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-28 [patent_title] => Human PD-L1 antibodies [patent_app_type] => utility [patent_app_number] => 17/277909 [patent_app_country] => US [patent_app_date] => 2020-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 10 [patent_no_of_words] => 10983 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17277909 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19923019 [patent_doc_number] => 12297290 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-13 [patent_title] => Method for generating multispecific antibodies from monospecific antibodies [patent_app_type] => utility [patent_app_number] => 16/849223 [patent_app_country] => US [patent_app_date] => 2020-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 63385 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 410 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16849223 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18492270 [patent_doc_number] => 11697681 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-11 [patent_title] => Anti-annexin A2 monoclonal antibodies [patent_app_type] => utility [patent_app_number] => 16/848828 [patent_app_country] => US [patent_app_date] => 2020-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 56 [patent_no_of_words] => 13951 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 514 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16848828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283786 [patent_doc_number] => 20200277388 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => TRISPECIFIC ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 16/845924 [patent_app_country] => US [patent_app_date] => 2020-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42506 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 4 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16845924 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16468221 [patent_doc_number] => 20200369758 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => BISPECIFIC ANTIGEN BINDING PROTEINS [patent_app_type] => utility [patent_app_number] => 16/843763 [patent_app_country] => US [patent_app_date] => 2020-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14533 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16843763 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16770901 [patent_doc_number] => 10981990 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Antibody molecules to TIM-3 and uses thereof [patent_app_type] => utility [patent_app_number] => 16/841029 [patent_app_country] => US [patent_app_date] => 2020-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 35 [patent_no_of_words] => 78829 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16841029 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16268866 [patent_doc_number] => 20200270353 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => COILED COIL IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF [patent_app_type] => utility [patent_app_number] => 16/835171 [patent_app_country] => US [patent_app_date] => 2020-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 85528 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16835171 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18675124 [patent_doc_number] => 20230312708 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELLS (CAR-T) FOR THE TREATMENT OF HEMATOLOGICAL AND SOLID TUMOR CANCERS [patent_app_type] => utility [patent_app_number] => 17/598200 [patent_app_country] => US [patent_app_date] => 2020-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34938 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -66 [patent_words_short_claim] => 221 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17598200 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16297822 [patent_doc_number] => 20200283545 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => MONOCLONAL ANTIBODIES AGAINST BCMA [patent_app_type] => utility [patent_app_number] => 16/821895 [patent_app_country] => US [patent_app_date] => 2020-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45482 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16821895 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16720131 [patent_doc_number] => 20210087278 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => ANTI-cMET ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/820143 [patent_app_country] => US [patent_app_date] => 2020-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24095 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16820143 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16628741 [patent_doc_number] => 20210047394 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/817993 [patent_app_country] => US [patent_app_date] => 2020-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33462 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 618 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16817993 [rel_patent_id] =>[rel_patent_doc_number] =>)